SPRB Stock — Spruce Biosciences, Inc. Common Stock

Spruce Biosciences, Inc. Common Stock (SPRB)

Updated October 16, 2026.

SPRB is a Stock. Total return is -96.9% over the past 6 years, 235.5 points behind SPY at 138.6%.

Spruce Biosciences is a biopharmaceutical company developing novel therapies for neurological and rare disorders, including enzyme replacement therapy for Sanfilippo Syndrome Type B, a treatment for depression, and a therapy for Congenital Adrenal Hyperplasia. The company does not currently distribute income to shareholders. This security appeals primarily to growth-oriented investors with risk tolerance for early-stage drug development, as the company is pre-revenue or early-stage with its pipeline candidates.

SPRB performance versus SPY

Price and return data through 2026-10-16.

Total return is -96.9% over the past 6 years, 235.5 points behind SPY at 138.6%. Over the past year its total return — price change plus distributions reinvested — is -74.7%. Its deepest 1-year drawdown was 75.3%.

SPRB key facts

Asset type

Stock

Asset class

Equity

Inception date

10/09/2020

Distribution frequency

None

Last close

$39.65 (as of 2026-10-16)

Market cap

$113,954,615

Average volume

88430.0

Beta

3.361

Payout ratio

0.0%

Forward P/E

8.3357

EPS

$-39.07

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SPRB risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 75.3%.

Who may consider SPRB — and who may not

It is a weaker fit for investors who need monthly cash flow (SPRB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SPRB

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions